5-Amino-1MQ vs AOD-9604: Two Fat-Loss Compounds That Haven't Proven It

5-Amino-1MQ and AOD-9604 get sold to the same person: someone who wants a compound that strips fat without the work, without the side effects, and without the prescription. Both are pitched with confident, mechanism-heavy marketing. Both are research-chemical-market staples. And both share the one flaw that should decide the question before any of the biology matters — neither has been proven to cause meaningful fat loss in humans.

The honest headline first: AOD-9604 actually has human data, and it pointed the wrong way — its developer ran a large obesity trial that reportedly failed to beat placebo, and the program was abandoned. 5-Amino-1MQ has no human data at all; its entire fat-loss case lives in mice. That is the strange heart of this comparison. The compound with more evidence is the one whose evidence is negative, and the compound with no negative result simply has no result. Neither is a proven fat-loss agent, and the difference between them is a difference in how they failed to prove it.

What Each One Actually Is

These are not the same kind of molecule, and the difference matters to the marketing.

5-Amino-1MQ is a small molecule — not a peptide, despite where it's sold — that inhibits an enzyme called NNMT (nicotinamide N-methyltransferase). The theory is that blocking NNMT preserves nicotinamide, supports NAD⁺, and pushes fat cells toward burning more energy. The foundational finding is real: knocking down NNMT protected mice from diet-induced obesity¹, and a small-molecule inhibitor in this chemical class reversed diet-induced obesity in mice². Every one of those results is rodent.

AOD-9604 is a peptide — a modified fragment corresponding roughly to amino acids 176–191 of human growth hormone, the region that carries growth hormone's fat-metabolizing (lipolytic) action³. It was engineered to reproduce GH's fat-burning effect while shedding the IGF-1-raising, growth-promoting, blood-sugar-affecting parts. In mice and fat cells it did exactly that. Then it went further than 5-Amino-1MQ ever has: into a real human obesity trial.

The Decisive Difference: One Was Tested in Humans

This is the whole story, so it's worth being precise about it.

AOD-9604 was not a vague idea that never got tested. It was developed as a serious clinical drug candidate by an Australian biotech and taken into human obesity trials in the 2000s. The pivotal human result — a large, placebo-controlled obesity trial running into hundreds of participants — did not show clinically meaningful weight loss over placebo. The developer did not advance it to approval, and the obesity program was discontinued. That failed trial is the single most decisive piece of evidence about AOD-9604 for fat loss in humans, and it points away from the marketing.

An honesty caveat that the AOD-9604 page makes clearly: that trial's full results were communicated largely through company and pipeline-review channels rather than published as a standalone peer-reviewed randomized-controlled-trial paper indexed in the medical literature. So the firmest claim is narrow but real — AOD-9604 has no published, peer-reviewed human trial showing meaningful fat loss, and the clinical program built to prove exactly that was abandoned. When a drug's own developer runs the trial and then walks away, that absence is itself a result.

5-Amino-1MQ never got that far. There is no published, controlled human clinical trial showing it causes fat loss, raises NAD⁺, or improves body composition in people. It has not failed a human trial — it simply has never had one. That sounds like it might be a point in its favor, but it isn't: an untested compound and a tested-and-failed compound are both, equally, unproven. The mouse data that 5-Amino-1MQ rests on is exactly the kind of "it worked in rodents" evidence that AOD-9604 also had — right before its human trial came up empty.

Mechanism vs Proof

Both compounds are sold on mechanism, and both mechanisms are genuinely interesting. That's the trap.

5-Amino-1MQ's NNMT story is mechanistically coherent: NNMT is a real metabolic enzyme, inhibiting it should spare nicotinamide and free up methyl groups, and in mice that translated into resistance to obesity. AOD-9604's story is equally clean: isolate GH's lipolytic domain, stimulate fat breakdown, skip the growth signaling. On paper, both look like what a fat-loss drug should look like.

The lesson of AOD-9604 is precisely that an elegant mechanism is not a result. AOD-9604 had the better-developed mechanistic case of the two — direct comparisons against full growth hormone, clear lipolysis data, a plausible safety profile — and it still failed the only test that counts. That history should make anyone more skeptical of 5-Amino-1MQ's even-earlier mechanistic story, not less. If the more-developed compound couldn't clear the human bar, a compound that hasn't even attempted it deserves no benefit of the doubt. The recurring theme across our peptides for fat loss coverage is exactly this: mouse mechanism is a reason to run a trial, never a substitute for one.

The Shared Reality: Unapproved and Unregulated

Whatever separates them on evidence, the practical reality is nearly identical.

Neither is FDA-approved as a weight-loss medicine. Both are sold, in practice, as grey-market "research chemicals" labeled "for research use only" or "not for human consumption" — which means no regulator is verifying the identity, dose, or purity of what's in the capsule or vial. AOD-9604 carries an extra wrinkle for tested athletes: as a growth-hormone fragment it sits on the anti-doping radar, with dedicated detection assays developed for doping control. The community dosing protocols you'll find circulating — covered, with the same caveats, on our 5-Amino-1MQ dosage page — are not validated by human trials for either compound.

Comparison at a Glance

Bottom Line

Put side by side, the verdict is uncomfortable for both. AOD-9604 has the more complete scientific record — real animal data and a real human trial — but that human trial is the problem: it reportedly failed to beat placebo, and the program was abandoned. 5-Amino-1MQ has a genuinely interesting NNMT mechanism and striking mouse data, but not a single controlled human trial to its name. So neither is a proven fat-loss agent. The difference is that AOD-9604's promise was tested and didn't deliver, while 5-Amino-1MQ's promise simply hasn't been tested at all.

If you're choosing between them on the basis of "which one works," the honest answer is that neither has earned that claim. One has a negative human result; the other has no human result. For where the genuinely evidence-backed options sit and the research tools and calculators we use to keep these claims honest, start there before you start anywhere else.